Meditope Biosciences Raises $3.6M in Series A Funding

Meditope Biosciences, Inc., a Los Angeles, CA-based biotechnology company developing antibody-based cancer products, raised $3.6m in Series A funding.

Backers included unnamed angel investors.

The company intends to use the funds to advance its proprietary monoclonal antibody (mAb) linker technology platform.

Led by Stephanie Hsieh, president and chief executive officer, Meditope Biosciences develops antibody-based cancer products. Discovered at City of Hope, a National Cancer Institute designated Comprehensive Cancer Center, the company’s technology can turn any mAb into a proprietary, site-specific “Lego-like” system that attaches and detaches drugs to antibodies without the need for chemical conjugation. The result is a memAb (meditope-enabled mAb) product that could offer multiple manufacturing advantages compared to existing antibody drug conjugate technologies.

In addition to the funding, Meditope also expanded its leadership team with Elisabeth Gardiner, Ph.D., an experienced scientific executive, as chief scientific officer.



Join the discussion